Previous Article | Next Article ![]()
Journal of Clinical Microbiology, October 2000, p. 3656-3662, Vol. 38, No. 10
Advanced Diagnostics Division, Dade Behring
Inc., San Jose,1 and Department of
Medicine, Stanford University Medical Center, Palo
Alto,2 California
Received 19 April 2000/Returned for modification 1 June
2000/Accepted 31 July 2000
A novel method for the detection of any alteration within a defined
sequence has recently been demonstrated (A. Lishanski, N. Kurn, and
E. F. Ullman, Nucleic Acids Res. 28:E42, 2000; A. Lishanski, Clin.
Chem. 46:9, 2000). Essential to this method are the generation of
partial duplexes that are capable of forming four-stranded structures
and the ability to detect inhibition of branch migration in these
structures (I. G. Panyutin and P. Hsieh, J. Mol. Biol.
230:413-424, 1993). Inhibition of branch migration indicates the
presence of sequence alteration. This mutation detection method, termed
branch migration inhibition (BMI), is suitable for the detection of
drug resistance in M. tuberculosis, which is frequently
associated with multiple mutations within known genes. We describe the
genotypic determination of the rifampin (RMP) and pyrazinamide (PZA)
susceptibilities of M. tuberculosis isolates, using BMI
coupled with the luminescence oxygen channeling immunoassay (LOCI)
(E. F. Ullman et al., Proc. Natl. Acad. Sci. USA 91:5426-5430,
1994). RMP and PZA resistances are associated with multiple mutations
within the rpoB and pncA genes, respectively.
M. tuberculosis genomic DNA samples prepared from 46 clinical isolates were used for genotypic determination of RMP
resistance in a "blind study." Similarly, PZA resistance was
determined using genomic DNA samples prepared from 37 clinical isolates. Full agreement of the genotypic and phenotypic determinations of drug susceptibility was demonstrated. RMP susceptibility
determination directly from cells of 10 clinical isolates grown in
culture was also demonstrated. The genotypic result of only 1 out of 10 isolates did not agree with the phenotypic susceptibility testing
result. Sequence analysis of the rpoB gene of this clinical
isolate revealed a single base substitution, most likely a silent point
mutation. The new BMI-LOCI mutation detection method is a rapid and
accurate procedure for the genotypic determination of the RMP and PZA
susceptibilities of M. tuberculosis clinical isolates. BMI
can also be detected by using commercially available automated
enzyme-linked immunosorbent assay plate formats (Lishanski et al.,
Nucleic Acids Res. 28:E42, 2000).
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Genotypic Determination of Mycobacterium tuberculosis
Antibiotic Resistance Using a Novel Mutation Detection Method, the
Branch Migration Inhibition M. tuberculosis Antibiotic
Resistance Test
*
Corresponding author. Mailing address: Advanced
Diagnostics Division, Dade Behring Inc., 3403 Yerba Buena Rd. (M/S
E1-304), San Jose, CA 95135. Phone: (408) 239-2081. Fax: (408)
239-2707. E-mail: yenping_liu{at}dadebehring.com.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»